FDA's Overreach on Compounded Peptides The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype Peptides are surging in popularity. There's little evidence that they work. In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for